Literature DB >> 2127569

Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects.

K M McErlane1, J Axelson, R Vaughan, C R Kerr, J D Price, L Igwemezie, G Pillai.   

Abstract

The disposition of tocainide enantiomers were examined in healthy human subjects and uraemic patients following a single i.v. dose (200 mg) of racemic tocainide hydrochloride. In the healthy subjects, the total body clearance of R(-)-tocainide was significantly greater than that of S(+)-tocainide (2.62 vs 1.70 ml.min-1.kg-1). Renal clearance also favoured R(-)-tocainide and appeared to contribute significantly to the stereoselective total body clearance. The volume of distribution of the enantiomers did not differ significantly. Uraemia produced a marked decrease in the total body clearance with no apparent effect on the volume of distribution of both enantiomers. The S/R ratio for total body clearance decreased significantly from 0.66 in healthy subjects to 0.54 in the uraemics, while the ratio for terminal elimination half-life significantly increased from 1.43 to 1.59. These results indicate that uraemia alters the degree of stereoselectivity in the pharmacokinetic parameters of tocainide enantiomers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127569     DOI: 10.1007/bf00315413

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

Review 1.  Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns; E W Wuis; E J Veringa
Journal:  Biochem Pharmacol       Date:  1988-01-01       Impact factor: 5.858

Review 2.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 3.  On chiral drug action.

Authors:  M Simonyi
Journal:  Med Res Rev       Date:  1984 Jul-Sep       Impact factor: 12.944

Review 4.  Serum tocainide enantiomer concentrations in human subjects.

Authors:  A J Sedman; J Gal; W Mastropaolo; P Johnson; J D Maloney; T P Moyer
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

5.  Serum binding of tocainide and its enantiomers in human subjects.

Authors:  A J Sedman; D C Bloedow; J Gal
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1982-10

Review 6.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

7.  Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.

Authors:  D Lalka; M B Meyer; B R Duce; A T Elvin
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

Review 8.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

9.  Effects of tocainide enantiomers on experimental arrhythmias produced by programmed electrical stimulation.

Authors:  A C Uprichard; J D Allen; D W Harron
Journal:  J Cardiovasc Pharmacol       Date:  1988-02       Impact factor: 3.105

10.  New antiarrhythmic agents. 1. Primary alpha-amino anilides.

Authors:  E W Byrnes; P D McMaster; E R Smith; M R Blair; R N Boyes; B R Duce; H S Feldman; G H Kronberg; B H Takman; P A Tenthorey
Journal:  J Med Chem       Date:  1979-10       Impact factor: 7.446

View more
  1 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.